Antibiotic Resistant Infection Deaths on Track to Increase 70 Percent by 2050

If at first you don't succeed, try and try again.

Antibiotic Resistant Infection Deaths on Track to Increase 70 Percent by 2050

The Vaccine Reaction reported:

A recent study projects that deaths around the world due to infections that are resistant to existing antibiotics could increase nearly 70% by 2050.

These antibiotic-resistant “superbugs” are fueled by what is known as antimicrobial resistance (AMR) caused by overuse and misuse of antibiotics as well as over-sanitization efforts.

The World Health Organization (WHO) has called AMR “one of the top global public health and development threats.” The study published in The Lancet last month states that from 2025 to 2050, the world could see more than 39 million deaths directly attributed to AMR.

Research from the U.S. Centers of Disease Control and Prevention and the Pew Charitable Trusts shows that nearly one in three antibiotics prescribed at outpatient facilities is unnecessary.

Antibiotics are ineffective against viruses such as SARS-CoV-2 or the flu.

Earlier this year, the WHO presented findings of “extensive overuse” of antibiotics during the peak years of the COVID-19 pandemic.

Its data suggested that approximately 75% of patients were treated with antibiotics “just in case”, despite only 8% of patients hospitalized with COVID-19 having bacterial co-infections.

Two Studies Find SARS-CoV-2 Virus Becoming Resistant to Antiviral Drugs Used to Treat Patients

MedicalXPress reported:

Two studies have found that the virus that causes COVID-19 is becoming resistant to two drugs used to treat patients with infections.

In the first study, a combined team from Cornell University and the National Institutes of Health studied the treatment outcomes for patients with compromised immune systems who were given the drug remdesivir.

They have published their results in the journal Nature Communications.

In the second study, a team of researchers from the University of Pittsburgh, Brigham and Women’s Hospital, Stanford University and Harvard University studied the outcomes for COVID-19 patients given antiviral drugs over the years 2021 to 2023.

They published their results in the journal JAMA Network Open.

The Defender